The evaluation of therapeutic effect and safety of rosiglitazone combined with metformin on incipient type 2 diabetes

Objective To investigate the therapeutic effect of rosiglitazone combined with metformin on incipient type 2 diabetes,and to evaluate the safety. Methods A total of 180 patients with incipient type 2 diabetes were randomly divided into rosiglitazone group,metformin group and rosiglitazone combined with metformin group,with 60 patients in each group. The patients in three groups were respectively administered with rosiglitazone,metformin and rosiglitazone plus metformin for 24 weeks. The levels of HbA1c,FBG,2h BG,FINS,HOMA-IR,HOMA-IAI,BMI,TC,TG and adverse reactions ( ADR) in the three groups were determined and observed. Results After treatment,the levels of FBG,2 h BG,FINS,HbA1c,TC and TG in three groups were significantly decreased,as compared with those before treatment ( P 0. 05 or P 0. 01). However,the levels of FBG,2 h BG and BMI in rosiglitazone combined with metformin group were significantly decreased,as compared with those in the other two groups ( P 0. 05) ,and FINS was significantly decreased,as compared with that of metformin group ( P 0. 05). The increase in HOMA-IAI in rosiglitazone combined with metformin group was also significant diference,as compared with that in the other two groups ( P 0. 05) ; the incidence of ADR in rosiglitazone combined with metformin group was also lower than that of the other two groups. Conclusion Rosiglitazone combined with metformin shows a better effect on incipient type 2 diabetes and low ADR,which can serve as an ideal therapy for type 2 diabetes.